Targets › COL3
2 programs from 1 company in 2 trials: 2 Phase 1; Other; next expected readout May 2029.
Open in Phaseline: the race on COL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Krystal Biotech | KB301 Replication-incompetent, non-integrating HSV-1 vector expressing human type III collagen | COL3 | Phase 1 | Skin Roughness | May 2029 |
| Krystal Biotech | KB304 HSV-1 vector delivering human collagen (COL3) and elastin (tropoelastin) genes | COL3, ELN | Phase 1 | Wrinkles in Decolletage | – |
Skin Roughness (1) Wrinkles in Decolletage (1)
protein or peptide (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.